Citations (84)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Fatma Gizem Avci, Ilgaz Tastekil, Amit Jaisi, Pemra Ozbek Sarica & Berna Sariyar Akbulut. (2023) A review on the mechanistic details of OXA enzymes of ESKAPE pathogens. Pathogens and Global Health 117:3, pages 219-234.
Read now
Read now
Anisha Thapa, Milan Kumar Upreti, Nabin Kishor Bimali, Basudha Shrestha, Anil Kumar Sah, Krishus Nepal, Binod Dhungel, Sanjib Adhikari, Nabaraj Adhikari, Binod Lekhak & Komal Raj Rijal. (2022) Detection of NDM Variants (blaNDM-1, blaNDM-2, blaNDM-3) from Carbapenem-Resistant Escherichia coli and Klebsiella pneumoniae: First Report from Nepal. Infection and Drug Resistance 15, pages 4419-4434.
Read now
Read now
Iain J. Abbott, Jason A. Roberts, Joseph Meletiadis & Anton Y. Peleg. (2021) Antimicrobial pharmacokinetics and preclinical in vitro models to support optimized treatment approaches for uncomplicated lower urinary tract infections. Expert Review of Anti-infective Therapy 19:3, pages 271-295.
Read now
Read now
Juan Carlos García-Betancur, Tobias Manuel Appel, German Esparza, Ana C Gales, Gabriel Levy-Hara, Wanda Cornistein, Silvio Vega, Duilio Nuñez, Luis Cuellar, Luis Bavestrello, Paulo F. Castañeda-Méndez, Juan M. Villalobos-Vindas & María Virginia Villegas. (2021) Update on the epidemiology of carbapenemases in Latin America and the Caribbean. Expert Review of Anti-infective Therapy 19:2, pages 197-213.
Read now
Read now
Articles from other publishers (80)
Olga Lomovskaya, Mariana Castanheira, Jill Lindley, Debora Rubio-Aparicio, Kirk Nelson, Ruslan Tsivkovski, Dongxu Sun, Maxim Totrov, Jeffery Loutit & Michael Dudley. (2023)
In vitro
potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing
Enterobacterales
. Antimicrobial Agents and Chemotherapy 67:11.
Crossref
Crossref
Satish Bhavsar, Sanjeev Joshi, Vikas Deshmukh, Shivaji Pawar, Bharat Dond, Amit Mishra, Abhijeet K. Kayastha, Ravindra Yeole, Prasad Deshpande, Sachin Bhagwat & Mahesh Patel. (2023) Design and development of an efficient convergent synthetic strategy for novel β-lactam enhancer zidebactam (WCK 5107). Chemical Papers.
Crossref
Crossref
Megan BergkesselBarbara Forte & Ian H. Gilbert. (2023) Small-Molecule Antibiotic Drug Development: Need and Challenges. ACS Infectious Diseases 9:11, pages 2062-2071.
Crossref
Crossref
Andrea Vila Domínguez, Irene Molina Panadero & Younes Smani. (2023) In vitro and in vivo evaluation of two combined β-lactamase inhibitors against carbapenem-resistant Acinetobacter baumannii. European Journal of Clinical Microbiology & Infectious Diseases 42:11, pages 1317-1325.
Crossref
Crossref
Joanna Krajewska, Piotr Chyży, Krzysztof Durka, Patrycja Wińska, Krystiana A. Krzyśko, Sergiusz Luliński & Agnieszka E. Laudy. (2023) Aromatic Diboronic Acids as Effective KPC/AmpC Inhibitors. Molecules 28:21, pages 7362.
Crossref
Crossref
Rachel A. Powers, Cynthia M. June, Micah C. Fernando, Erin R. Fish, Olivia L. Maurer, Rachelle M. Baumann, Trevor J. Beardsley, Magdalena A. Taracila, Susan D. Rudin, Kristine M. Hujer, Andrea M. Hujer, Nicolò Santi, Valentina Villamil, Maria Luisa Introvigne, Fabio Prati, Emilia Caselli, Robert A. Bonomo & Bradley J. Wallar. (2023)
Synthesis of a Novel Boronic Acid Transition State Inhibitor, MB076: A Heterocyclic Triazole Effectively Inhibits
Acinetobacter
-Derived Cephalosporinase Variants with an Expanded-Substrate Spectrum
. Journal of Medicinal Chemistry 66:13, pages 8510-8525.
Crossref
Crossref
Krisztina M Papp-Wallace, Sarah M McLeod & Alita A Miller. (2023)
Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against
Acinetobacter
Species
. Clinical Infectious Diseases 76:Supplement_2, pages S194-S201.
Crossref
Crossref
Ashraf A. Kadry, May A. El-Antrawy & Amira M. El-Ganiny. (2023) Impact of short chain fatty acids (SCFAs) on antimicrobial activity of new β-lactam/β-lactamase inhibitor combinations and on virulence of Escherichia coli isolates. The Journal of Antibiotics 76:4, pages 225-235.
Crossref
Crossref
Vincenzo Di Pilato, Luigi Principe, Lilia Andriani, Noemi Aiezza, Marco Coppi, Silvia Ricci, Tommaso Giani, Francesco Luzzaro & Gian Maria Rossolini. (2023) Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam. Clinical Microbiology and Infection 29:4, pages 537.e1-537.e8.
Crossref
Crossref
Geetika Dhanda, Yash Acharya & Jayanta Haldar. (2023) Antibiotic Adjuvants: A Versatile Approach to Combat Antibiotic Resistance. ACS Omega 8:12, pages 10757-10783.
Crossref
Crossref
Yasinalli Tamboli, Jaydeo T. Kilbile, Vikas Deshmukh, Vipul Rane, Ravikumar Tadiparthi, Ravindra Yeole & Arvind Y. Merwade. (2023) Process Development and Scale-Up of the Novel β-Lactamase Inhibitor WCK 6395. Organic Process Research & Development 27:3, pages 496-504.
Crossref
Crossref
Lekshmi Narendrakumar, Medha Chakraborty, Shashi Kumari, Deepjyoti Paul & Bhabatosh Das. (2023) β-Lactam potentiators to re-sensitize resistant pathogens: Discovery, development, clinical use and the way forward. Frontiers in Microbiology 13.
Crossref
Crossref
Tomefa E Asempa, Abigail K Kois, Christian M Gill & David P Nicolau. (2023) Phenotypes, genotypes and breakpoints: an assessment of β-lactam/β-lactamase inhibitor combinations against OXA-48. Journal of Antimicrobial Chemotherapy 78:3, pages 636-645.
Crossref
Crossref
Yasinalli Tamboli, Jaydeo T. Kilbile & Arvind Y. Merwade. (2023) Large-Scale Amide Coupling in Aqueous Media: Process for the Production of Diazabicyclooctane β-Lactamase Inhibitors. Organic Process Research & Development 27:1, pages 120-128.
Crossref
Crossref
Natalia G. Vallianou, Alexandros Skourtis, Dimitris Kounatidis, Evangelia Margellou, Fotis Panagopoulos, Eleni Geladari, Angelos Evangelopoulos & Edison Jahaj. (2023) The Role of the Respiratory Microbiome in the Pathogenesis of Aspiration Pneumonia: Implications for Diagnosis and Potential Therapeutic Choices. Antibiotics 12:1, pages 140.
Crossref
Crossref
Aliaa Fouad, Richard Quintiliani, David P Nicolau & Tomefa E Asempa. (2023) Relative bioavailability of crushed tebipenem administered through a nasogastric tube with and without enteral feeding. Journal of Antimicrobial Chemotherapy 78:1, pages 205-208.
Crossref
Crossref
Angel J. Magaña, Jan Sklenicka, Clemencia Pinilla, Marc Giulianotti, Prem Chapagain, Radleigh Santos, Maria Soledad Ramirez & Marcelo E. Tolmasky. (2023) Restoring susceptibility to aminoglycosides: identifying small molecule inhibitors of enzymatic inactivation. RSC Medicinal Chemistry.
Crossref
Crossref
Nikol Kadeřábková, Ayesha J.S. Mahmood, R. Christopher D. Furniss & Despoina A.I. Mavridou. 2023.
221
307
.
João Gonçalves Pereira, Joana Fernandes, Ana Rita Duarte & Susana Mendes Fernandes. (2022) β-Lactam Dosing in Critical Patients: A Narrative Review of Optimal Efficacy and the Prevention of Resistance and Toxicity. Antibiotics 11:12, pages 1839.
Crossref
Crossref
Filomena Sannio, Antonella Brizzi, Rosita Del Prete, Marialuce Avigliano, Tiziana Simone, Carlotta Pagli, Teresa Ferraro, Filomena De Luca, Marco Paolino, Federico Corelli, Claudia Mugnaini & Jean-Denis Docquier. (2022) Optimization of Pyrazole Compounds as Antibiotic Adjuvants Active against Colistin- and Carbapenem-Resistant Acinetobacter baumannii. Antibiotics 11:12, pages 1832.
Crossref
Crossref
L. He, H. Yang, J. Sun, L. Zhai, J. Ji, X. Ma, D. Tang, Y. Mu, L. Wang, Z. Iqbal & Z. Yang. (2023) Synthesis and β-Lactamase Inhibition Activity of Diazabicyclooctane Derivatives in Combination with Imipenem. Russian Journal of General Chemistry 92:12, pages 2888-2898.
Crossref
Crossref
Priyanka Gehlot & Hariprasad P. (2022) Computational and data mining studies to understand the distribution and dynamics of Temoneria (TEM) β-lactamase and their interaction with β-lactam and β-lactamase inhibitors. Environmental Pollution 314, pages 120289.
Crossref
Crossref
Tomefa E Asempa, Abigail K Kois, Christian M Gill & David P Nicolau. (2022) Phenotypes, genotypes and breakpoints: an assessment of β-lactam/ β-lactamase inhibitor combinations against OXA-48. Journal of Antimicrobial Chemotherapy 77:10, pages 2622-2631.
Crossref
Crossref
Wei Yu, Ping Shen, Qixia Luo, Luying Xiong & Yonghong Xiao. (2022) Efficacy and safety of novel carbapenem–β-lactamase inhibitor combinations: Results from phase II and III trials. Frontiers in Cellular and Infection Microbiology 12.
Crossref
Crossref
Alain Philippon, Guillaume Arlet, Roger Labia & Bogdan I. Iorga. (2022) Class C β-Lactamases: Molecular Characteristics. Clinical Microbiology Reviews 35:3.
Crossref
Crossref
Gian Marco Tuveri, Matteo Ceccarelli, Alessandro Pira & Igor V. Bodrenko. (2022) The Optimal Permeation of Cyclic Boronates to Cross the Outer Membrane via the Porin Pathway. Antibiotics 11:7, pages 840.
Crossref
Crossref
Fredrika Rajer, Lisa Allander, Philip A. Karlsson & Linus Sandegren. (2022) Evolutionary Trajectories toward High-Level β-Lactam/β-Lactamase Inhibitor Resistance in the Presence of Multiple β-Lactamases. Antimicrobial Agents and Chemotherapy 66:6.
Crossref
Crossref
Neha K. Prasad, Ian B. Seiple, Ryan T. Cirz & Oren S. Rosenberg. (2022) Leaks in the Pipeline: a Failure Analysis of Gram-Negative Antibiotic Development from 2010 to 2020. Antimicrobial Agents and Chemotherapy 66:5.
Crossref
Crossref
K. Raja Reddy, Maxim Totrov, Olga Lomovskaya, David C. Griffith, Ziad Tarazi, Matthew C. Clifton & Scott J. Hecker. (2022) Broad-spectrum cyclic boronate β-lactamase inhibitors featuring an intramolecular prodrug for oral bioavailability. Bioorganic & Medicinal Chemistry 62, pages 116722.
Crossref
Crossref
Igor V. Bodrenko, Stefan Milenkovic & Matteo Ceccarelli. (2022) Diffusion of molecules through nanopores under confinement: Time-scale bridging and crowding effects via Markov state model. Biomolecular Concepts 13:1, pages 207-219.
Crossref
Crossref
Ayşegül Saral Sariyer. (2022) Three new inhibitors of class A β-lactamases evaluated by molecular docking and dynamics simulations methods: relebactam, enmetazobactam, and QPX7728. Journal of Molecular Modeling 28:4.
Crossref
Crossref
Philipp Thelen, Anne Santerre Henriksen, Christopher Longshaw, Yoshinori Yamano, Ben Caldwell & Axel Hamprecht. (2022) In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany. Journal of Global Antimicrobial Resistance 28, pages 12-17.
Crossref
Crossref
Vincenzo Di Pilato, Lucia Henrici De Angelis, Noemi Aiezza, Ilaria Baccani, Claudia Niccolai, Eva Maria Parisio, Cesira Giordano, Giulio Camarlinghi, Simona Barnini, Silvia Forni, Lorenzo Righi, Maria Teresa Mechi, Tommaso Giani, Alberto Antonelli & Gian Maria Rossolini. (2022) Resistome and virulome accretion in an NDM-1-producing ST147 sublineage of Klebsiella pneumoniae associated with an outbreak in Tuscany, Italy: a genotypic and phenotypic characterisation. The Lancet Microbe 3:3, pages e224-e234.
Crossref
Crossref
Olga Lomovskaya, Debora Rubio-Aparicio, Ruslan Tsivkovski, Jeff Loutit & Michael Dudley. (2022)
The Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 Restores the Potency of Multiple Oral Beta-Lactam Antibiotics against Beta-Lactamase-Producing Strains of Resistant
Enterobacterales
. Antimicrobial Agents and Chemotherapy 66:2.
Crossref
Crossref
Juan Carlos Vázquez-Ucha, Cristina Lasarte-Monterrubio, Paula Guijarro-Sánchez, Marina Oviaño, Laura Álvarez-Fraga, Isaac Alonso-García, Jorge Arca-Suárez, German Bou & Alejandro Beceiro. (2022)
Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing
Enterobacterales
. Antimicrobial Agents and Chemotherapy 66:2.
Crossref
Crossref
Jayaseelan Murugaiyan, P. Anand Kumar, G. Srinivasa Rao, Katia Iskandar, Stephen Hawser, John P. Hays, Yara Mohsen, Saranya Adukkadukkam, Wireko Andrew Awuah, Ruiz Alvarez Maria Jose, Nanono Sylvia, Esther Patience Nansubuga, Bruno Tilocca, Paola Roncada, Natalia Roson-Calero, Javier Moreno-Morales, Rohul Amin, Ballamoole Krishna Kumar, Abishek Kumar, Abdul-Rahman Toufik, Thaint Nadi Zaw, Oluwatosin O. Akinwotu, Maneesh Paul Satyaseela & Maarten B. M. van Dongen. (2022) Progress in Alternative Strategies to Combat Antimicrobial Resistance: Focus on Antibiotics. Antibiotics 11:2, pages 200.
Crossref
Crossref
Zeenat A. Shyr, Yu-Shan Cheng & Wei Zheng. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
789
812
.
Farrukh Sobia, Shahazad Niwazi, Amani Awwadh Alotaibi & Hanan Abdullah Almaimani. 2022. Beta-Lactam Resistance in Gram-Negative Bacteria. Beta-Lactam Resistance in Gram-Negative Bacteria
81
92
.
Wei Yu, Yunbo Chen, Ping Shen, Jinru Ji, Chaoqun Ying, Zhiying Liu, Luying Xiong, Yunqing Qiu & Yonghong Xiao. (2021) Antibacterial Activity and Optimal Treatment of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Bloodstream Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae. Frontiers in Pharmacology 12.
Crossref
Crossref
Wei Yu, Luying Xiong, Qixia Luo, Yunbo Chen, Jinru Ji, Chaoqun Ying, Zhiying Liu & Yonghong Xiao. (2021) In Vitro Activity Comparison of Ceftazidime–Avibactam and Aztreonam–Avibactam Against Bloodstream Infections With Carbapenem-Resistant Organisms in China. Frontiers in Cellular and Infection Microbiology 11.
Crossref
Crossref
Scott A. Becka, Elise T. Zeiser, John J. LiPuma & Krisztina M. Papp-Wallace. (2021) Activity of Imipenem-Relebactam against Multidrug- and Extensively Drug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli. Antimicrobial Agents and Chemotherapy 65:11.
Crossref
Crossref
Firzan Nainu, Andi Dian Permana, Nana Juniarti Natsir Djide, Qonita Kurnia Anjani, Rifka Nurul Utami, Nur Rahma Rumata, Jianye Zhang, Talha Bin Emran & Jesus Simal-Gandara. (2021) Pharmaceutical Approaches on Antimicrobial Resistance: Prospects and Challenges. Antibiotics 10:8, pages 981.
Crossref
Crossref
Emilio Lence & Concepción González-Bello. (2021) Molecular Basis of Bicyclic Boronate β-Lactamase Inhibitors of Ultrabroad Efficacy – Insights From Molecular Dynamics Simulation Studies. Frontiers in Microbiology 12.
Crossref
Crossref
Jamie L. Wagner, Kylie C. Markovich, Katie E. Barber, Kayla R. Stover & Lauren R. Biehle. (2021) Optimizing rapid diagnostics and diagnostic stewardship in Gram‐negative bacteremia. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 41:8, pages 676-685.
Crossref
Crossref
Philipp Knechtle, Stuart Shapiro, Ian Morrissey, Cyntia De Piano & Adam Belley. (2021)
Sigmoid
E
max
Modeling To Define the Fixed Concentration of Enmetazobactam for MIC Testing in Combination with Cefepime
. Antimicrobial Agents and Chemotherapy 65:8.
Crossref
Crossref
Olga Lomovskaya, Ruslan Tsivkovski, Dongxu Sun, Raja Reddy, Maxim Totrov, Scott Hecker, David Griffith, Jeffery Loutit & Michael Dudley. (2021) QPX7728, An Ultra-Broad-Spectrum B-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological Characteristics. Frontiers in Microbiology 12.
Crossref
Crossref
Nichole K. Stewart, Marta Toth, Anastasiya Stasyuk, Sergei B. Vakulenko & Clyde A. Smith. (2021)
In Crystallo
Time-Resolved Interaction of the
Clostridioides difficile
CDD-1 enzyme with Avibactam Provides New Insights into the Catalytic Mechanism of Class D β-lactamases
. ACS Infectious Diseases 7:6, pages 1765-1776.
Crossref
Crossref
Olga Lomovskaya, Debora Rubio-Aparicio, Kirk Nelson, Dongxu Sun, Ruslan Tsivkovski, Mariana Castanheira, Jill Lindley, Jeffery Loutit & Michael Dudley. (2021)
In Vitro
Activity of the Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Multiple Beta-Lactam Antibiotics against Pseudomonas aeruginosa
. Antimicrobial Agents and Chemotherapy 65:6.
Crossref
Crossref
Magdalena Zalacain, Clarisse Lozano, Agustina Llanos, Nicolas Sprynski, Thomas Valmont, Cyntia De Piano, David Davies, Simon Leiris, Carole Sable, Adeline Ledoux, Ian Morrissey, Marc Lemonnier & Martin Everett. (2021)
Novel Specific Metallo-β-Lactamase Inhibitor ANT2681 Restores Meropenem Activity to Clinically Effective Levels against NDM-Positive
Enterobacterales
. Antimicrobial Agents and Chemotherapy 65:6.
Crossref
Crossref
Viivi H. A. Hirvonen, James Spencer & Marc W. van der Kamp. (2021) Antimicrobial Resistance Conferred by OXA-48 β-Lactamases: Towards a Detailed Mechanistic Understanding. Antimicrobial Agents and Chemotherapy 65:6.
Crossref
Crossref
Juan C. Vázquez-Ucha, Diana Rodríguez, Cristina Lasarte-Monterrubio, Emilio Lence, Jorge Arca-Suarez, María Maneiro, Eva Gato, Astrid Perez, Marta Martínez-Guitián, Carlos Juan, Antonio Oliver, German Bou, Concepción González-Bello & Alejandro Beceiro. (2021)
6-Halopyridylmethylidene Penicillin-Based Sulfones Efficiently Inactivate the Natural Resistance of
Pseudomonas aeruginosa
to β-Lactam Antibiotics
. Journal of Medicinal Chemistry 64:9, pages 6310-6328.
Crossref
Crossref
David T. Davies & Martin Everett. (2021) Designing Inhibitors of β-Lactamase Enzymes to Overcome Carbapenem Resistance in Gram-Negative Bacteria. Accounts of Chemical Research 54:9, pages 2055-2064.
Crossref
Crossref
Laura Berneking, Anna Both, Benjamin Berinson, Armin Hoffmann, Marc Lütgehetmann, Martin Aepfelbacher & Holger Rohde. (2020) Performance of the BD Phoenix CPO detect assay for detection and classification of carbapenemase-producing organisms. European Journal of Clinical Microbiology & Infectious Diseases 40:5, pages 979-985.
Crossref
Crossref
Donald J. AbrahamSebastian A. Testero, Leticia I. Llarrull, Jed F. Fisher & Shahriar Mobashery. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
188
.
Michiyoshi Nukaga, Michael J. Yoon, Magdalena A. Taracilia, Tyuji Hoshino, Scott A. Becka, Elise T. Zeiser, Joseph R. Johnson & Krisztina M. Papp-Wallace. (2021)
Assessing the Potency of β-Lactamase Inhibitors with Diverse Inactivation Mechanisms against the PenA1 Carbapenemase from
Burkholderia multivorans
. ACS Infectious Diseases 7:4, pages 826-837.
Crossref
Crossref
Kelly A. Cairns, Victoria Hall, Genevieve E. Martin, David W.J. Griffin, James D. Stewart, Sadid F. Khan, Iain J. Abbott, Zaal Meher‐Homji, Catherine O. Morrissey, Christopher Sia, Jane Love, Carmela E. Corallo, Peter Bergin, Ashish Sharma, Gopal Basu, Andrew Spencer & Anton Y. Peleg. (2020)
Treatment of invasive IMP‐4
Enterobacter cloacae
infection in transplant recipients using ceftazidime/avibactam with aztreonam: A case series and literature review
. Transplant Infectious Disease 23:2.
Crossref
Crossref
Anna N. Tevyashova & Mikhail V. Chudinov. (2021) Progress in the medicinal chemistry of organoboron compounds. Russian Chemical Reviews 90:4, pages 451-487.
Crossref
Crossref
Corneliu Ovidiu Vrancianu, Elena Georgiana Dobre, Irina Gheorghe, Ilda Barbu, Roxana Elena Cristian & Mariana Carmen Chifiriuc. (2021) Present and Future Perspectives on Therapeutic Options for Carbapenemase-Producing Enterobacterales Infections. Microorganisms 9:4, pages 730.
Crossref
Crossref
Rajeev Soman, Yamuna Devi Bakthavatchalam, Abinaya Nadarajan, Hariharan Triplicane Dwarakanathan, Ramasubramanian Venkatasubramanian & Balaji Veeraraghavan. (2020) Is it time to move away from polymyxins?: evidence and alternatives. European Journal of Clinical Microbiology & Infectious Diseases 40:3, pages 461-475.
Crossref
Crossref
Maxwell J. Lasko, Tomefa E. Asempa & David P. Nicolau. (2021) Pharmacodynamics of Ceftibuten: An Assessment of an Oral Cephalosporin against Enterobacterales in a Neutropenic Murine Thigh Model. Antibiotics 10:2, pages 201.
Crossref
Crossref
J.P. Bedos, G. Daikos, A.R. Dodgson, A. Pan, N. Petrosillo, H. Seifert, J. Vila, R. Ferrer & P. Wilson. (2021) Early identification and optimal management of carbapenem-resistant Gram-negative infection. Journal of Hospital Infection 108, pages 158-167.
Crossref
Crossref
John BremnerJohn Bremner. 2021. Multiple Action-Based Design Approaches to Antibacterials. Multiple Action-Based Design Approaches to Antibacterials
21
49
.
David T. Davies, Simon Leiris, Magdalena Zalacain, Nicolas Sprynski, Jérôme Castandet, Justine Bousquet, Clarisse Lozano, Agustina Llanos, Laethitia Alibaud, Srinivas Vasa, Ramesh Pattipati, Ravindar Valige, Bhaskar Kummari, Srinivasu Pothukanuri, Cyntia De Piano, Ian Morrissey, Kirsty HoldenPeter WarnFrancesca Marcoccia, Manuela Benvenuti, Cecilia Pozzi, Giusy Tassone, Stefano Mangani, Jean-Denis Docquier, David Pallin, Richard ElliotMarc Lemonnier & Martin Everett. (2020)
Discovery of
ANT3310
, a Novel Broad-Spectrum Serine β-Lactamase Inhibitor of the Diazabicyclooctane Class, Which Strongly Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacterales and
Acinetobacter baumannii
. Journal of Medicinal Chemistry 63:24, pages 15802-15820.
Crossref
Crossref
Dafna Yahav, Christian G. Giske, Alise Grāmatniece, Henrietta Abodakpi, Vincent H. Tam & Leonard Leibovici. (2020) New β-Lactam–β-Lactamase Inhibitor Combinations. Clinical Microbiology Reviews 34:1.
Crossref
Crossref
Juan C. Vázquez-Ucha, Jorge Arca-Suárez, Germán Bou & Alejandro Beceiro. (2020) New Carbapenemase Inhibitors: Clearing the Way for the β-Lactams. International Journal of Molecular Sciences 21:23, pages 9308.
Crossref
Crossref
Alessandro Pira, Mariano Andrea Scorciapino, Igor V. Bodrenko, Andrea Bosin, Silvia Acosta-Gutiérrez & Matteo Ceccarelli. (2020) Permeation of β-Lactamase Inhibitors through the General Porins of Gram-Negative Bacteria. Molecules 25:23, pages 5747.
Crossref
Crossref
I. G. Shemyakin, V. V. Firstova, N. K. Fursova, I. V. Abaev, S. Yu. Filippovich, S. G. Ignatov & I. A. Dyatlov. (2020) Next-Generation Antibiotics, Bacteriophage Endolysins, and Nanomaterials for Combating Pathogens. Biochemistry (Moscow) 85:11, pages 1374-1388.
Crossref
Crossref
Kirk Nelson, Debora Rubio-Aparicio, Ruslan Tsivkovski, Dongxu Sun, Maxim Totrov, Michael Dudley & Olga Lomovskaya. (2020)
In Vitro
Activity of the Ultra-Broad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Meropenem against Clinical Isolates of Carbapenem-Resistant Acinetobacter baumannii
. Antimicrobial Agents and Chemotherapy 64:11.
Crossref
Crossref
Matteo Bassetti, Vincenzo Di Pilato, Tommaso Giani, Antonio Vena, Gian Maria Rossolini, Anna Marchese & Daniele R Giacobbe. (2020) Treatment of severe infections due to metallo-β-lactamases-producing Gram-negative bacteria. Future Microbiology 15:15, pages 1489-1505.
Crossref
Crossref
Shivakumar S. Jalde & Hyun Kyung Choi. (2020) Recent advances in the development of β-lactamase inhibitors. Journal of Microbiology 58:8, pages 633-647.
Crossref
Crossref
Scott J. Hecker, K. Raja Reddy, Olga Lomovskaya, David C. Griffith, Debora Rubio-Aparicio, Kirk Nelson, Ruslan Tsivkovski, Dongxu Sun, Mojgan Sabet, Ziad Tarazi, Jonathan Parkinson, Maxim Totrov, Serge H. Boyer, Tomasz W. Glinka, Orville A. Pemberton, Yu Chen & Michael N. Dudley. (2020) Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases. Journal of Medicinal Chemistry 63:14, pages 7491-7507.
Crossref
Crossref
Kirk Nelson, Debora Rubio-Aparicio, Dongxu Sun, Michael Dudley & Olga Lomovskaya. (2020)
In Vitro
Activity of the Ultrabroad-Spectrum-Beta-Lactamase Inhibitor QPX7728 against Carbapenem-Resistant
Enterobacterales
with Varying Intrinsic and Acquired Resistance Mechanisms
. Antimicrobial Agents and Chemotherapy 64:8.
Crossref
Crossref
Maria Luisa Introvigne, Magdalena A. Taracila, Fabio Prati, Emilia Caselli & Robert A. Bonomo. (2020) α‐Triazolylboronic Acids: A Promising Scaffold for Effective Inhibitors of KPCs. ChemMedChem 15:14, pages 1283-1288.
Crossref
Crossref
Anna N. Tevyashova. (2020) Oxaborine Derivatives: Synthesis and Therapeutic Potential. Chemistry of Heterocyclic Compounds 56:6, pages 715-718.
Crossref
Crossref
Olga Lomovskaya, Kirk Nelson, Debora Rubio-Aparicio, Ruslan Tsivkovski, Dongxu Sun & Michael N. Dudley. (2020)
Impact of Intrinsic Resistance Mechanisms on Potency of QPX7728, a New Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases in
Enterobacteriaceae
, Pseudomonas aeruginosa, and Acinetobacter baumannii
. Antimicrobial Agents and Chemotherapy 64:6.
Crossref
Crossref
Olga Lomovskaya, Ruslan Tsivkovski, Kirk Nelson, Debora Rubio-Aparicio, Dongxu Sun, Maxim Totrov & Michael N. Dudley. (2020) Spectrum of Beta-Lactamase Inhibition by the Cyclic Boronate QPX7728, an Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases: Enhancement of Activity of Multiple Antibiotics against Isogenic Strains Expressing Single Beta-Lactamases. Antimicrobial Agents and Chemotherapy 64:6.
Crossref
Crossref
Ruslan Tsivkovski, Maxim Totrov & Olga Lomovskaya. (2020) Biochemical Characterization of QPX7728, a New Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases. Antimicrobial Agents and Chemotherapy 64:6.
Crossref
Crossref
Ruslan Tsivkovski & Olga Lomovskaya. (2020) Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam. Antimicrobial Agents and Chemotherapy 64:4.
Crossref
Crossref
Marco Coppi, Vincenzo Di Pilato, Francesco Monaco, Tommaso Giani, Pier Giulio Conaldi & Gian Maria Rossolini. (2020)
Ceftazidime-Avibactam Resistance Associated with Increased
bla
KPC-3
Gene Copy Number Mediated by pKpQIL Plasmid Derivatives in Sequence Type 258
Klebsiella pneumoniae
. Antimicrobial Agents and Chemotherapy 64:4.
Crossref
Crossref
Marianna Criscuolo & Enrico Maria Trecarichi. (2020) Ceftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current Experiences. Antibiotics 9:2, pages 58.
Crossref
Crossref